Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | STAT5A | P42229 | 1/20 | 0.38 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7670693 | 0.74 | SMARCA4 (0.41) | KDM4EHPGDHSD17B10DHFR | |
| SCHEMBL8284554 | 0.69 | ALDH1A1 (0.39) | KDM4EHPGD | |
| SCHEMBL5275339 | 0.68 | ALDH1A1 (0.36) | DHFR | |
| SCHEMBL29636156 | 0.67 | ALDH1A1 (0.50) | KDM4EHPGDHSD17B10DHFRSYK | |
| SCHEMBL23898662 | 0.67 | ALDH1A1 (0.50) | KDM4EHPGDHSD17B10DHFRSYK | |
| SCHEMBL8362866 | 0.65 | ATM (0.37) | PARP1KDM4EHPGDHSD17B10 | |
| SCHEMBL16389423 | 0.64 | ALDH1A1 (0.53) | KDM4EHPGDHSD17B10DHFR | |
| SCHEMBL29861263 | 0.64 | ALDH1A1 (0.53) | KDM4EHPGDHSD17B10DHFR | |
| SCHEMBL6981939 | 0.64 | PIM1 (0.42) | PARP1KDM4EHPGDHSD17B10JAK3 | |
| SCHEMBL7396812 | 0.62 | RPS6KA3 (0.43) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247641-B2 | Compounds, derivatives, compositions, preparation and uses | MGI GP, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247641-B2 | Compounds, derivatives, compositions, preparation and uses | MGI GP, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247641-B2 | Compounds, derivatives, compositions, preparation and uses | MGI GP, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| WO-2005053609-A2 | METHODS OF NAD+-DEPENDENT DEACETYLASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20040254372-A1 | Compounds, derivatives, compositions, preparation and uses | EISAI INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2003014121-A9 | COMPOUNDS, DERIVATIVES, COMPOSITIONS, PREPARATION AND USES | GUILFORD PHARM INC (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2003014121-A1 | COMPOUNDS, DERIVATIVES, COMPOSITIONS, PREPARATION AND USES | GUILFORD PHARMACEUTICALS INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254372-A1 | Compounds, derivatives, compositions, preparation and uses | PARP1, PARP2, PARP3 | PARP1 1/4885CDK5 40/4885CDK5R1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.